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OBSERVATION
Whipple Limbic Encephalitis
Fre´de´ric Blanc, MD, PhD; Kaouther Ben Abdelghani, MD; Fre´de´ric Schramm, MD; Benoit Jaulhac, MD, PhD;
Emmanuel Chatelus, MD; Christelle Sordet, MD; Jacques-Eric Gottenberg, MD, PhD; Jean Sibilia, MD, PhD
Objective: To describe a relapse ofWhipple disease re-
vealed by isolated limbic encephalitis with no other signs
of systemic involvement.
Design: Case report.
Setting: University Hospital of Strasbourg, Strasbourg,
France.
Patient: A 41-year-old patient.
Main Outcome Measures: Cognitive functions and
results of cerebrospinal fluid analysis and brain mag-
netic resonance imaging.
Results:A41-year-old patient was hospitalized for head-
ache associated with anterograde amnesia and temporo-
spatial disorientation.Whipple diseasewith systemicmani-
festationswasdiagnosed4yearspreviouslyand insufficiently
treated. The neuropsychological evaluation showed im-
paired episodic memory and executive functions. Analy-
sis of the cerebrospinal fluid showed increased lympho-
cytes and a positiveTropherymawhippleipolymerase chain
reaction result. Cerebral magnetic resonance imaging re-
vealed a typical pattern of limbic encephalitis with an in-
tense signal in the amygdalae and hippocampi. The out-
come under antibiotic treatment was marked by partial
improvement of the cognitive disorders, disappearance of
the positiveTwhipplei polymerase chain reaction result in
cerebrospinal fluid, and a clear decrease of inflammation
on brain magnetic resonance imaging.
Conclusions:Whipple disease can present as limbic en-
cephalitis. Few cases have been previously described in
the literature. Such diagnosis is of importance because
of the specific treatment.
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W HIPPLE DISEASE IS Asystemic bacterialinfection due toTropheryma whip-plei . Its clinical
manifestations generally include diar-
rhea, preceded in most cases by articular
symptoms.1 Involvement of the central ner-
vous system is possible, often being poly-
morphous but rarely isolated.2
Limbic encephalitis (LE) is related to in-
flammation of the medial temporal lobe.
Subacute amnesia is themain clinical symp-
tomandcanbe associatedwith seizures and
psychiatric symptoms suchasdepressionor
personality change. The main etiologies of
LE are paraneoplastic,3 autoimmune,4 and
viral, particularly herpetic LE. Excluding
neurosyphilis,5 very few bacterial infec-
tions are responsible for LE.
We report 1 case of a relapse ofWhipple
disease revealed by isolated LE with no
other signs of systemic involvement.
REPORT OF A CASE
A 41-year-old patient was hospitalized ur-
gently for headache associated with ma-
jor anterograde amnesia. These symp-
toms had developed progressively over
severalmonths. Therewasno fever, change
in the general state of health, or diarrhea.
Thepatientwas followedup forWhipple
disease revealed 4 years earlier by migra-
tory polyarthralgia, episodes of fever, and
intermittent diarrhea. The diagnosis had
been confirmedby aduodenal biopsy speci-
men that had shown inflammatory lesions
containing macrophages with inclusions
positive for periodic acid–Schiff. Results of
the T whipplei polymerase chain reaction
(PCR) assay on the duodenal biopsy speci-
men were, however, negative. A course of
antibiotics with a third-generation cepha-
losporin and cotrimoxazole had been pre-
scribed for 15 months, but this treatment
had not been maintained by the patient.
On hospital admission, the physical
neurological examination was normal
without meningeal syndrome. Con-
versely, a neuropsychological evaluation
confirmed the presence of important dis-
orders of the verbal and visual memory.
On the Free and Cued Selective Remind-
ing Test6 for verbal episodic memory, the
patient had a score of 8 of 16 words for
immediate recall (5th percentile) and
scores of 1 of 16 for free recall and 2 of 16
for total recall (5th percentile). In the
visual object recognition memory test
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(DMS48),7 the patient was deficient, with only 64% cor-
rect answers. The Mini-Mental State Examination score
was 19 (temporal orientation, 2 of 5; spatial orientation,
2 of 5; attention, 3 of 5; and recall, 0 of 3). There were
also disorders of the working memory (backward digit
span) and executive functions with an inhibition defect
in the go/no go test (error rate of 4 of 40) and defective
mental flexibility (error rate of 23 of 40 in the opposing
orders test). TheWechsler Adult Intelligence Scale score
likewise showed a retardation of the rate of processing
of information (5th percentile). The Rey-Osterrieth
complex figure copy was normal.8 The major and pre-
dominant effect on the episodic memory was in favor of
involvement of the Papez circuit, especially the areas of
the medial temporal lobes, while the rest of the cogni-
tive evaluation pointed to involvement of the frontal lobes
and, notably, orbitofrontal areas.
The immunological profile (antinuclear antibodies,
polynuclear neutrophil anticytoplasmic antibodies, and
antiendomysium antibodies) was negative. Immunologi-
cal tests for intraneuronal antibodies, by immunochem-
istry and immunoblot including anti-Hu, anti-Yo, anti-
Ri, antiamphiphysin, anti-CV2, anti-Ta, and Ma1, were
unremarkable. Results of Legionella, cytomegalovirus,
Epstein–Barr virus, human immunodeficiency virus, and
Lyme disease serologies were likewise negative and lev-
els of vitamins B1, B6, B9, and B12 were normal. Analysis
of the cerebrospinal fluid (CSF) revealed 335 leukocytes/
mm3with 99% lymphocytes, and results ofTwhippleiPCR
targeting a 191 base pair–specific fragment of the 16S ri-
bosomalDNAwere positive on 2 different aliquots of CSF.
The specificity was confirmed by direct sequencing of the
amplified DNA fragment showing 100% similarity with
T whipplei DNA only. Results of PCR for Herpesviridae
(including herpes simplex virus 1, herpes simplex virus
2, varicella-zoster virus, cytomegalovirus, and humanher-
pesvirus 6) were negative. Results of the T whipplei PCR
assay were negative on a duodenal biopsy specimen.
Brain magnetic resonance imaging showed diffuse
gadolinium enhancement of the leptomeninges and hy-
perintensity in both themedial temporal lobes and amyg-
dalae on T2 and fluid-attenuated inversion recovery se-
quences and present to a lesser degree in the insular and
frontobasal regions, evoking the diagnosis of meningo-
encephalitis with limbic involvement (Figure, A).
The electroencephalogram displayed a well-
organized cycle of wake and sleep and there was no ictal
or interictal pattern. Ophthalmologic examination of the
eye revealed the existence of left posterior hyalitis with
discrete retinal hemorrhage, possibly evoking the pres-
ence of Whipple disease uveitis.
Treatment with a third-generation cephalosporin, tri-
methoprim-sulfamethoxazole, doxycycline, and hydroxy-
chloroquine was initiated for a period of 2 years. Cortico-
therapy at a dose of 30mg/dwas administered for 6weeks.
The evolution was marked by a very clear regression
of the cognitive disorders with correct inhibition (no er-
ror on the go/no go test), a normal mental flexibility (2
errors on the opposing order test), and normal speed of
information processing (normal Wechsler Adult Intelli-
gence Scale score). The Mini-Mental State Examination
score was 25 (temporal orientation, 4 of 5; attention, 3
of 5; and recall, 1 of 3). The disturbance of working
memory remained unchanged. The episodicmemory par-
tially improved, with maximal scores of 11 words of 16
for immediate recall, 1 of 16 for free recall, and 4 of 16
for total recall on the Free and Cued Selective Remind-
ing Test at 3 months and 4 of 16 for free recall and 11 of
16 for total recall at 1 year. On the DMS48 visual recog-
nition test, the patient displayed great improvement and
gave 94% and 98% correct answers at 3 months and 1
year, respectively. A new search of T whipplei by PCR in
CSF was negative after 1 month of treatment. Fol-
low-up brainmagnetic resonance imaging performed af-
ter 3 months and 1 year showed a diminution of the in-
ternal temporal hypersignal (Figure, B). Conversely, an
atrophy of the hippocampus appeared with persistence
of a discrete uptake of contrast in the right temporal un-
cus and at the base of the third ventricle.
COMMENT
This relapse of Whipple disease has the particularity that
it was revealed by LE. Involvement of the central nervous
system is rare inWhipple disease but represents the most
serious complication.9 It occurs during evolutionof the dis-
ease in 10% to 20% of patients.10 In 2002, Gerard et al2 de-
scribed in a literature review 122 patients with neuro-
Whipple disease. Among these individuals, only 21
displayed isolated initial neurological involvement, while
themajority had developed other extraneurologicalmani-
festations.Neurological symptoms appear especially in pa-
tientswhose treatment has not included antibiotics able to
cross the blood-brain barrier.11
The neurological manifestations of Whipple disease
are extremely diverse and poorly specific. Cognitive im-
pairment is the most frequent and is detected in 71% of
patients with neurological involvement.12 These disor-
ders affect memory (25% of cases) and orientation (24%
of cases) and can even lead to dementia (28% of cases).2
Oculomasticatorymyorrhythmia, always associatedwith
vertical supranuclear gaze palsy, is detected in 8% to 20%
of patients and has important diagnostic value as it is en-
countered only in Whipple disease.2,13
Brain magnetic resonance imaging shows lesions in
53% of cases.12 These lesions consist of T2 or T2-
A B
Figure. Axial T2-weighted fluid-attenuated inversion recovery brain magnetic
resonance imaging. A, At the acute phase, showing an intense signal in the
amygdalae and hippocampi. B, One year later, showing mild atrophy of the
amygdalae and hippocampi.
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weighted fluid-attenuated inversion recovery hyperin-
tensities, with or without T1 contrast enhancing, lo-
cated in themedial part of the temporal lobe, hypothalamic
region, or pons.14 Forty-two percent of patients also have
mild to moderate atrophy.12 In our patient, the lesions
were localized in the hippocampi and the amygdalae, typi-
cal of LE, with clear inflammation (Figure, A). One year
later, there was atrophy of these structures (Figure, B).
The involvement of the medial temporal lobe was con-
firmed by cognitive tests that showed impairment of ver-
bal—without improvement by cueing—and visual
memory. To our knowledge, in the literature, no case of
Whipple disease was described as a “limbic encephali-
tis.” But we found 10 cases, including ours, with cogni-
tive impairment and brain magnetic resonance imaging
described that correspond to such a syndrome.9,14-21 Cases
with necropsy have also demonstrated the frequent in-
volvement of the amygdala and the hippocampus (25%).22
Results of CSF PCR analysis have been found to be
negative in more than 30% of cases during neurological
involvement ofWhipple disease.23,24 Conversely, in some
patients, results of the PCR assay remain positive in CSF
despite antibiotic treatment and sometimes persist for
years, without clinical relapse. This positivity can indi-
cate either the persistence of an infectious agent insuf-
ficiently controlled by antibiotics or the persistence of
residual DNA from dead organisms, which explains the
controversial interest of PCR in therapeutic follow-up.13
In our patient, results of the PCR assay became negative
after 1 month of antibiotic treatment.
Therapeutic recommendations are not based on any
controlled trial. The strategy normally proposed is the
administration of 160 mg of trimethoprim and 800 mg
of sulfamethoxazole twice daily for 1 to 2 years, but re-
lapse is possible.11 In neurological forms of the disease,
a combination of hydroxychloroquine, cyclines, and sul-
fadiazine has been proposed,25 while according to Coo-
per et al,26 in the case of neurological relapse while tak-
ing trimethoprim-sulfamethoxazole, cefixime can be quite
efficacious. Hence, we opted in our case for triple anti-
biotherapy in association with hydroxychloroquine.
The prognosis in the event of involvement of the cen-
tral nervous system remains somber, with a mortality of
more than 25% at 4 years. One-quarter of the patients
have severe sequelae.27 The evolution of our patient’s dis-
ease was marked by partial persistence of the amnesia.
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